Skip to content

Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout

Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout - a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05998161
Acronym
LAVENDER
Enrollment
290
Registered
2023-08-18
Start date
2023-09-04
Completion date
2024-06-22
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burnout, Stress

Brief summary

In this single-blinded randomized controlled clinical trial 290 patients with stress or burnout will be investigated regarding the effectiveness of a digital therapeutic for improvement of stress level, the unguided online intervention reviga. Inclusion criteria are: age 18-65 years, ICD-10 diagnosis Z73, operationalized as above average general stress level (PSS score \> 21) and increased levels of work-related stress / burnout (OLBI score ≥ 2.18), living in Germany, working a minimum of 20h per week, having a stable treatment for at least 30 days at the time of inclusion, and consent to participation. Exclusion criterion is having plans to change the treatment in the upcoming three months at the time of inclusion. Patients will be randomized and allocated to either an intervention group, receiving reviga in addition to treatment as usual (TAU), or a control group, receiving only TAU. The control group will be granted access to the program at the end of the study. Primary endpoint will be the perceived stress measured by the PSS score, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be anxiety symptoms, level of functioning, burnout symptoms, health-related quality of life, and sick days.

Interventions

BEHAVIORALreviga

Participants will receive access to the digital health intervention reviga in addition to TAU.

Sponsors

University Hospital Schleswig-Holstein
CollaboratorOTHER
Hannover Medical School
CollaboratorOTHER
Gaia AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

All endpoints are patient-reported outcome measures (PROMs). Given that participants are aware of their study group (receiving reviga in addition to treatment as usual or only receiving treatment as usual), this trial is not blinded.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age 18-65 years * living in Germany * employed (minimum of 20h/week) * ICD-10 diagnosis Z73, operationalized as above average general stress level (PSS score \> 21) and increased levels of work-related stress / burnout (OLBI score ≥ 2.18) * stable treatment (psychotherapy, medication, no treatment) for at least 30 days at the time of inclusion * consent to participation

Exclusion criteria

* plans to change treatment (psychotherapy, medication, ...) in the upcoming three months at the time of inclusion

Design outcomes

Primary

MeasureTime frameDescription
Stress symptoms3 monthsPerceived Stress Scale (PSS-10). Total score ranging from 0-40; higher scores mean more stress symptoms (worse outcome).

Secondary

MeasureTime frameDescription
Stress symptoms6 monthsPerceived Stress Scale (PSS-10). Total score ranging from 0-40; higher scores mean more stress symptoms (worse outcome).
Anxiety symptoms3 months, 6 monthsGeneralized Anxiety Assessment (GAD-7). Total score ranging from 0-21; higher scores mean higher anxiety (worse outcome).
Functioning3 months, 6 monthsWork and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).
Burnout symptoms3 months, 6 monthsOldenburg Burnout Inventory (OLBI). Two subscales (exhaustion and disengagement), each ranging from 8-32; higher scores mean higher burnout symptoms (worse outcome).
Health-related quality of life3 months, 6 monthsAssessment of Quality of Life - 8D (AQoL-8D). AQoL-8D score ranging from 0-100; higher scores mean higher quality of life (better outcome).
Sick days3 months, 6 monthsNumber of sick days in the past 3 months

Other

MeasureTime frameDescription
hospital stays3 months, 6 monthsNumber of hospital stays in the past 3 months
curative stays3 months, 6 monthsNumber of curative stays in the past 3 months
doctor visits3 months, 6 monthsNumber of doctor visits in the past 3 months
Effort and reward imbalance3 months, 6 monthsEffort-reward-imbalance (ERI). Three subscales: effort, ranging from 3-12, higher scores mean higher effort; reward, ranging from 7=28, higher scores mean higher reward; over-commitment, ranging from 6-24, higher scores mean higher over-commitment. Ratio effort/reward: scores \>1 mean more efforts for each reward (worse outcome).
Depressive symptoms3 months, 6 monthsPatient Health Questionnaire - 9 item version (PHQ-9). Total score ranging from 0-27; higher scores mean higher depressive symptoms (worse outcome).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026